Stiris Research Inc. Announces First Patient Dosed in Phase II Retinal Vein Occlusion Study

London, ON — August 25, 2022 —

Stiris Research Inc. (“Stiris”) is an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the first patient dosed in a Phase II Retinal Vein Occlusion (RVO) study.

“We want to thank our sites for their ongoing interest in the data, additional Canadian sites were added in record time during the last few months, which have already enrolled have participants and while we actively continuing recruiting and screening for other sites,” said Sabrina Ramkellawan, Project Manager.

Retinal vein occlusion (RVO) is a blockage of the small veins that carry blood away from the retina. The retina is the layer of tissue at the back of the inner eye that converts light images to nerve signals and sends them to the brain. Retinal vein occlusion is most often caused by hardening of the arteries (atherosclerosis) and the formation of a blood clot. The risk of these disorders increases with age, therefore retinal vein occlusion most often affects older people.


About Stiris Research

Stiris Research Inc. is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.